COVID-19 serological survey using micro blood sampling

Melissa M. Matthews[1†], Tae Gyun Kim[1†], Satoshi Shibata[1†], Noriko Shibata[1], Christian

Butcher[2], Jaekyung Hyun[1], Keon Young Kim[1], Theodore Robb[3], Siang Sheng Jheng[3], Masashi

Narita[4], Tomoari Mori[5], Mary Collins[6] & Matthias Wolf[1]*

[1]Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology

Graduate University (OIST), Onna-son, Okinawa, Japan.

[2]Fluid Mechanics Unit, OIST, Onna-son, Okinawa, Japan.

[3]IT Division, Infrastructure Section, OIST, Onna-son, Okinawa, Japan.

[4]Okinawa Chubu Hospital, Division of Infectious Diseases, Okinawa City, Okinawa, Japan

[5]Research Support Division, Occupational Health and Safety, OIST, Onna-son, Okinawa,

Japan.

[6]Research Support Division, Office of the Provost, OIST, Onna-son, Okinawa, Japan.

[†]these authors have contributed equally

*Correspondence to *matthias.wolf@oist.jp*

Abstract

During August 2020, we carried out a serological survey among students and employees at

the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing

for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used

a FDA-authorized 2-step ELISA protocol developed by the Krammer Lab (*1*, *2*) in combination

with at-home self-collection of blood samples using a custom low-cost finger prick-based

capillary blood collection kit. Although our survey did not find any COVID-19 seropositive

individuals among the OIST cohort, it reliably detected all positive control samples obtained

from a local hospital and excluded all negatives controls. Among our controls, we found

strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in

the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with

patient-based capillary blood collection using as little as one drop of blood can reliably assess

the seroprevalence among communities. Anonymous sample tracking and an integrated

website created a stream-lined procedure. Major parts of the workflow were automated on

a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype

for reliable serological testing among larger populations.

Background and Introduction

At the beginning of 2020, COVID-19 emerged from Hubei province in southern China and

quickly spread across the globe. Due to its proximity and direct flight connections between

the epicenter in Wuhan and its capital Tokyo, the Japanese Nation was among the first to

experience cases of the disease outside China, documenting its first case on January 15, 2020.

In early April, as the tourism season in Okinawa began to ramp up, so did the new cases of

COVID-19 in Okinawa. A first wave of COVID-19 cases peaked at the moderate rate of 10

cases/day in mid-April (total number 132 cases), which was effectively reduced by 5 weeks of

lock-down measures to no additional cases within the next two months. From early August

on, however, a second, much stronger wave of infections has, at the time of this report,

culminated in more than 2,682 accumulated cases on the island (October 8, 2020). The

present study was conducted at the beginning of this second wave.

Serological surveys which detect the presence of antibodies against SARS-CoV-2

antigens can provide important information to the government for issuing health care

guidelines. At the beginning of April 2020, we obtained plasmids for coronavirus surface

antigens from the Krammer Lab at the Icahn School of Medicine (NY, NY, USA). We established

protein expression and purification in a mammalian cell line and set up an ELISA following the

2-step assay developed by the same group (*1*). Their assay has received emergency use

authorization by the U.S. Food & Drug Administration (FDA) (*2*). We secured PCR-confirmed

human sera from COVID-19 positive patients at the local hospital as well as negative controls

from serum collected before December 2019. Once the assay itself was validated, we set up

partially automated sample handling on a robotic liquid handler, established a website with

a barcoding system for anonymous sample tracking, and conducted a serological survey of

staff and students at our institution.

In emergency situations such as during COVID-19, the health care system is under

stress; it cannot be expected that trained clinical personnel are available to draw patient

blood by venous puncture. Furthermore, non-essential human traffic in hospitals and other

health care institutions should ideally be limited to protect vital health care workers from risk

of exposure to potential carriers of the virus. To overcome this limitation, we distributed easy-

to-use, self-administered micro blood sampling kits to participants. The kit uses a single-use

safety lancet to collect a few drops of capillary blood from the participant's finger. We show

that antibody titers obtained by micro blood sampling are equivalent to serum antibody titers

from blood drawn by conventional venous puncture. This low-cost, easily deployable self-

sampling method in combination with a highly sensitive and specific ELISA in a centralized

testing lab provides a scalable solution that can enable serological surveys of larger

populations.

Methods

Protein Expression and Purification

Plasmids for mammalian expression of the SARS-CoV-2 S (spike) protein receptor-binding

domain (RBD, residues 319-541) and stabilized His-tagged SARS-CoV-2 S including a T4 foldon

trimerization tag were generously provided by Florian Krammer and colleagues at the Icahn

School of Medicine (NY, NY, USA) (*3*). Proteins were expressed in Expi293F cells and purified

by Ni-NTA affinity and size-exclusion chromatography as described previously (*1*). The yield

was 15 mg/L and 4 mg/L for RBD and the trimeric SARS-CoV-2 S, respectively. 500 µL aliquots

of purified protein at a concentration of 10 µg/mL were frozen in liquid nitrogen and stored

at -80 °C until use. We expressed and purified both the SΔcs (furin cleavage site deletion RRAR

to A) and SΔcspp construct (cleavage site deletion and stabilizing mutations K986P and V987P)

(*3*), but only the SΔcs protein was used in this study. Protein purity was verified by SDS-PAGE

and confirmed by Western blot with MonoRab™ Anti-His Tag (C-term) Antibody (Nr. 25B6E11,

GenScript, USA).

Electron microscopy

The quality and folding of two proteins, the RBD and SARS-CoV-2 S, were verified by

biochemical methods and correct folding and assembly of the trimeric spike protein was

confirmed using cryo-electron microscopy (Figure 1). Sample solution was applied to a carbon

coated copper grid and stained with 1 % uranyl acetate. The protein particles were visualized

with a Talos L120 transmission electron microscope (Thermo Fisher Scientific, USA) operating

at 120 kV acceleration voltage.

For cryo-EM, 3 µL of purified trimeric spike sample solution was applied to UltrAuFoil

R1.2/1.3 grids pre-treated with a Solarus advanced plasma system (Model 950, Gatan, USA)

for 60 seconds at 25 °C in a 23 % H_2, 77 % O_2 gas mix. The grids were blotted and vitrified in a

Vitrobot Mark IV (Thermo Fisher Scientific, USA) using a liquid ethane-propane mixture. Cryo-

EM grids and particle density were optimized by screening based on protein concentration in

the range of 2-3 mg/mL. Particles Images of trimeric spike protein in amorphous ice were

collected with a Titan Krios transmission electron microscope (Thermo Fisher Scientific, US)

operating at 300 kV on a Falcon-3EC camera (Thermo Fisher Scientific, US) in counting mode,

at a pixel size of 1.08 Å (at the specimen level). Frames from 1,479 movies were aligned, dose-

weighted and summed using motioncor2 (*4*). Contrast transfer function (CTF) estimation,

particle picking and 2D classification were performed with RELION 3.1 (*5*). A total of 1,119,504

particles were picked semi-automatically, of which 297,144 particles were retained after 2D

classification.

Sample collection and heat inactivation

The micro blood sampling kits were assembled in 8x12 cm sealable plastic bags, including BD

Microtainer® contact-activated lancet (Becton Dickison, NJ, USA), blood collection tube

containing a coagulant and a separator gel (Greiner Bio-one MiniCollect® TUBE 0.5/0.8 CAT

Serum Separation Clot Activator gold cap), packaged alcohol wipes, adhesive bandage, and

peelable sticker with a linear tube barcode (Code 128) and a matching QR code encoding a

link to our website. After finger prick with the safety lancet, users collected 1-5 drops (approx.

30-150 µL) of capillary blood into the serum separation tube and attached the linear barcode.

Serum separation tubes were centrifuged at 5,000 $\times$ g for 5 min at 4 °C under biosafety level

2 (BSL2) conditions, then inactivated in a water bath at 56 °C for 1 hr. Heat-inactivated

samples were stored at 4 °C until use for ELISA. After scanning tube barcodes for each plate

into a CSV file with a hand-held scanner, separated serum was transferred into barcoded 96-
well plates using manual pipetting.
124
ELISA and automation
We followed the 2-step ELISA protocol developed by the Krammer lab (*1*). ELISA plate formats
were modified as depicted in Supplemental Figure 1C. Modified plate designs included two
dilution series of positive control, which provided an internal standard. Additional negative
controls were included to provide a cutoff that was consistently within the suggested range
of 0.15-0.2 AU (Absorbance Units) at 492 nm.
We implemented a partially automated workflow on a Beckman Biomek FX^P (Beckman
Coulter, Indianapolis, IN, USA) liquid handling robot for two steps of the ELISA protocol,
namely, for (i) dilution and transfer of serum samples for RBD screening plates and for (ii)
plate developing and reading of all plates. Plates were stacked to maximize throughput and
usage of available deck space. Automated dilution and transfer of serum samples utilized a
96-well plate containing 5X diluted serum in PBS, termed the D1 (dilution 1) plate as a source
plate. Sample from the D1 plate was diluted with a PBS-T milk solution in a second 96-well
plate, termed the D2 (dilution 2) plate, and finally transferred to the destination ELISA plate
according to the published protocol (*1*). After dilution, D1 plates were immediately wrapped
in parafilm and stored at 4 ^{O}C. If a given sample tested positive against RBD antigen in step 1,
a fresh 5x diluted sample was prepared using solution remaining in the serum separation
tubes. If the volume of the remaining serum was insufficient, the 5x diluted sample from the
D1 plate was used for the confirmatory step 2.
For automated plate development and reading, 100 µL of Sigma*Fast*^{TM} OPD
development solution (Sigma Aldrich) was prepared according to the described protocol and
added to all wells. A wait time was programmed in the liquid handler workflow so that exactly
10 minutes after addition of OPD, 50 µL of 3 M HCl were added to quench the reaction.
Immediately after addition of HCl to a given plate, the plate was automatically loaded into
and read on a DTX800 multimode plate reader (Beckman Coulter, Indianapolis, IN, USA) at
492 nm wavelength. Functions were added within the automation code to automatically
calculate threshold values for each plate and output a "positive" or "negative" result for each

sample. All other steps, including washing on an AquaMax 4000 plate washer (Molecular
Devices LLC, San Jose, CA, USA), were carried out manually.

Controls and Standards

Three positive controls in the form of intravenous blood sera from confirmed SARS-CoV-2
PCR-positive patients (collected 10-30 days post onset of symptoms) were obtained from
Naha Municipal Hospital, Naha, Japan. After titer analysis of all three samples (data not
shown), the two samples with the strongest titers were pooled and used as the positive
control for all assays. Positive controls (collected at least 90 days after onset of symptoms)
for validation of the capillary blood collection method were obtained from Okinawa Chubu
Hospital, Uruma City, Japan. Negative controls taken from patients prior to November 2019
were obtained from Naha Municipal Hospital from intravenous blood, and from a commercial
serum pool (Human Serum from human male AB plasma, Sigma Aldrich H4522-100ML, Batch
#SLCD1948, serum was pooled prior to August 2019). Human MERS-convalescent serum and
SARS-CoV-2 convalescent plasma (NIBSC code 20/130) were obtained from the National
Institute of Biological Standards and Control, UK.

Calculation of thresholds

The threshold for each step 1 plate was defined as the average of the negative controls plus
3 standards deviations of the negative controls as described previously (*1*). The average and
median threshold for all step 1 plates was 0.161 AU and 0.166 AU, respectively. Initially, the
threshold for the step 2 plate was calculated in the same manner as step 1. However, the
threshold calculated with only three negative controls was below the recommended range
(0.15-0.2 AU at 492 nm). Therefore, another threshold, calculated as 4-times the average
blank, which has been demonstrated to be valid for identifying anti-SARS-CoV-2 antibody-
positive samples was used instead (*6*). Average and median threshold for all step 2 plates
were 0.196 AU and 0.1868 AU, respectively.

Calculation of predictivity values

The positive predictivity value (PPV) describes the likelihood that a sample which tests
positive is a true positive. The negative predictivity value (NPV) describes the likelihood that

a sample which tests negative is a true negative (*7*). Estimated predictivity values were
calculated using the following equations:

positive predictivity value

$$= \frac{sensitivity \times prevalence}{(sensitivity \times prevalence) + (1 - specificity)(1 - prevalence)}$$

negative predictivity value

$$= \frac{specificity \times (1 - prevalence)}{[(1 - sensitivity) \times prevalence] + [specificity \times (1 - prevalence)]}$$

Website-based platform for test application and anonymous results reporting

Test results were disseminated using a custom web application developed by the OIST IT
section and deployed through Microsoft Azure cloud. The front page (Supplementary Figure
1B) contained a disclaimer, an instructional video (Supplemental Information), a printable
instruction sheet, and other basic information for participants.

The QR code printed and included in each blood sample collection kit was encoded
with a unique web URL corresponding to the sample ID of the sticker placed on the sample
tube (Supplemental Figure 1A). Following a simple user flow (Supplemental Figure 2),
participants could check their test results anonymously either by scanning the QR code with
a smartphone or by entering the 6-digit sample ID matching the linear tube barcode.

Upon inputting a valid sample ID, participants were prompted to accept a disclaimer
before viewing results. After accepting the disclaimer, participants were able to retrieve the
status of their sample, including guidance on interpreting test results. Optional information
about gender, prior symptoms, age, travel history could be entered voluntarily. This metadata
was   collected   anonymously   through   a   survey   on   the   SurveyMonkey
(https://www.surveymonkey.com*)* platform and linked to the sample ID which was passed as
a hidden field via the participant's web browser. Each sample ID was stored in a database
table along with values representing test results and disclaimer acceptance. The web
application queried this database to retrieve the status of the requested sample ID. The
sample IDs were composed of six characters generated randomly from the set of
alphanumeric characters (a-zA-Z0-9), excluding letters O, I, l, Z, Q and numbers 0, 1, 2, 9 to

minimize human read errors. Out of approximately 10^{10} combinations, 1000 unique IDs were

randomly selected. Some additional security features, such as request rate limiting, were

implemented to restrict the use of automated tools to retrieve results for all possible sample

IDs. Basic functions were developed to allow batch import and export of test results in a

delimited text format, allowing easy transfer of data between the testing system and the web

application database.

Sequence alignments

The full-length sequences of SARS-CoV, MERS-CoV S protein (UniProt ID: P59594 and K9N5Q8,

respectively) were aligned pairwise using ClustalW2, against the SΔcs sequence (*3*)

(Supplementary Figure 3).

Human subject research approval

The experiments were conducted according to a proposal approved by the OIST human

subjects ethics committee (application HSR-2020-026).

Results

Protein preparation and validation

SARS-CoV-2 trimeric spike and its receptor-binding domain (RBD) were expressed in

mammalian cells and purified. The quality was verified by Western blot and electron

microscopy. We performed single particle cryo-EM and 2D-image classification. This

confirmed that the trimeric spike protein was properly folded and assembled (Figure 1).

Figure 1. A. SDS-PAGE of expressed and purified RBD and spike proteins. Lane: 1,

molecular weight marker; 2, cell lysate of expressed RBD; 3, purified RBD; 4, cell lysate

of expressed SARS-CoV-2 S; 5, purified spike; 6 and 7, Western blot of purified RBD

and spike, respectively. **B and C.** Electron micrographs of negatively stained purified

RBD and spike protein, respectively. **D.** 2D class averages from boxed aligned single-

particle cryo-EM images of the trimeric spike protein, showing secondary structure

elements indicative of proper folding. Box size 28 nm. Scale bars 20 nm 100 nm in B

and C, respectively.

Validation of micro blood sampling method.

Serum samples are typically separated from intravenously collected blood. To confirm that

the finger-prick method neither causes unforeseen complications nor affects assay sensitivity,

blood samples from two confirmed SARS-CoV-2 PCR-positive individuals were taken both

intravenously and by finger-prick on the same day. Although these samples were collected at

least 92 days post exposure, they retained a high antibody titer comparable to positive

controls, which were collected 10-30 days post onset of symptoms.

The MiniCollect® capillary blood collection tube contains a prefilled volume of a

polymer gel with a lithium heparin coagulant, which induces blood clotting and can separate

the blood clot from serum by centrifugation. Separated serum from four samples were tested

in a dilution series in duplicate on both an RBD-coated ELISA plate and a trimeric spike-coated

ELISA plate according to the "step 2" ELISA protocol (*1*) (see Methods and modified plate

layout in Supplementary Figure 1C). For both individuals, titers of intravenous and capillary

blood were similar on both the RBD-coated and the spike-coated plate (Figure 2).

Figure 2: Comparison of serum antibody titers from intravenously collected blood
and capillary blood obtained by finger prick. Individuals A and B provided blood
samples both intravenously and also by micro-blood collection at least 90 days post
exposure. Each sample was tested in duplicate on the same ELISA plate, either coated
with SARS-CoV-2 spike RBD (left) or with SARS-CoV-2 trimeric spike protein (right).
Each replicate is plotted. Line connects average values. Positive control was pooled
serum collected from two SARS-CoV-2 PCR-positive individuals 10-30 days after onset
of symptoms. Negative controls were collected from individuals prior to November
2019.

Serological Survey

Overall, 675 sample tubes were collected and processed. Among all the samples received,

zero samples showed signal above threshold in both the RBD screening plate and the spike

confirmatory plate.

Samples were typically collected, serum separated, and heat-inactivated at the end of

each day. Nonetheless, most blood samples can be stored at room temperature in the serum

separation tube for several days, in some cases with larger blood volume for up to 1 week.

Longer than 1 week is not recommended because the blood begins to dry up. Antibody titers

after serum separation have been reported as stable for up to 6 weeks when stored at 4 °C

(*8*). Some participants had difficulty collecting their blood by themselves. In such cases, we

encouraged participants to visit the nurses in our institute's Health Center for assistance.

The results for RBD ELISA step 1 are summarized in Figure 3A. Intensities were scaled

with respect to the threshold for each plate. Results were compared with multiple negative

controls and a collection of serum samples from SARS-CoV-2 PCR positive individuals. A subset

of 63 OIST samples had serum antibody reactivity above the established threshold, and only

a few were at the same level as the PCR-positive individuals. Titers from all PCR-positive

individuals were above the threshold. Samples from all PCR-positive individuals were taken

by capillary blood collection at least one month post onset of symptoms.

Results for the final ELISA step 2 are shown in Figure 3B. Of the 63 OIST samples that

were positive in RBD step 1, all had serum antibody reactivity below threshold for all 5

dilutions when tested against the SARS-CoV-2 trimeric spike protein in step 2, indicating a

9.9% false positive rate in the highly sensitive step 1. Samples from all PCR positive individuals

were above the threshold for at least two dilutions. Results were classified as "positive"

(above threshold), "negative" (below threshold), or "undetermined". The most common

cause of an undetermined result was the failure to provide sufficient serum. This was the case

for 40 of the 675 samples that we received. If the result was undetermined, the participant

was encouraged to pick up another kit and try again.

From the SurveyMonkey platform, 206 completed surveys were received, or 31 % of

all samples collected. The collective results showed that 17 % of the survey takers believed

that they had experienced some COVID-19 symptoms in the past 6 months and 31 % had

travelled outside of Okinawa in the past 6 months. The age distribution was as follows: 20-40

years old, 60 %; 40-60 years, 36 %; greater than 60 years, 4 %. The gender distribution was

roughly equal.

Figure 3: Summary of OIST Serological Survey. A. In assay step 1 (anti-RBD ELISA), 63 OIST samples were above the threshold (3 standard deviations above the average negative control). **B.** All positives from step 1 were tested in step 2 (anti-spike ELISA). No OIST samples were above the threshold (4 times the average background). **C.** Step-2 titers were measured at dilutions 1:100, 1:300, 1:900, 1:2700, and 1:8100. Positive controls showed much stronger signal than the OIST samples even at high dilution. The dotted line indicates the respective threshold level. All negative controls are samples taken from patients prior to November 2019. Sera from PCR positive individuals were collected at least 10-30 days post onset of symptoms.

Assay Specificity

The specificity of the Mount Sinai Hospital Clinical Laboratory COVID-19 ELISA Antibody Test has been reported as 100 % for 74 negative control samples (*9*) and the developers demonstrated no cross-reactivity against the common coronavirus strain NL63 (*3*). Of note, as part of the protocol establishing process, we used a SARS-CoV-2 convalescent plasma (NIBSC code 20/130) and human MERS-convalescent serum to confirm the specificity of the assay in both steps. As expected, SARS-CoV-2 convalescent plasma showed strong reactivity in both plates. MERS-convalescent serum, on the other hand, was negative in anti-RBD cross-reactivity, but positive in anti-spike cross-reactivity (Figure 4).

To understand the basis of the MERS-convalescent serum cross-reactivity, we performed an

amino acid sequence alignment of SARS-CoV-2 spike and MERS-CoV spike protein. Sequence

alignment demonstrated that the SARS-CoV-2 RBD shares 18.7 % identity with MERS-CoV RBD,

but alignment of the full-length spike sequence demonstrated higher 32.3 % sequence

identity between SARS-CoV-2, and MERS-CoV (Supplementary Figure 3).

Figure 4: Titers of SARS-CoV-2 and MERS-CoV convalescent serum in RBD and spike

ELISA. Each sample was tested in duplicate on the same plate. Line connects average

values. Positive control is pooled serum from two CoV-2 PCR positive individuals 10-

30 days after onset of symptoms. Negative control is from a commercial serum pool.

Discussion

Micro blood sampling is a good alternative to venous blood collection

Micro blood sampling by finger prick at home avoids unnecessary risk and effort by healthcare

workers and allows parallel collection of large numbers of samples within a short period of

time. The combination of patient-driven sample self-collection with a standardized highly

specific and selective ELISA in a centralized lab improves the reliability of results while keeping

costs low. Serum can be separated from whole blood up to 1 week after collection. Provided

that temperatures are kept close to ambient temperature, this would allow for shipping of

samples from collection site to the testing site by mail. The main bottleneck is serum transfer

from collection tube to ELISA plate. This step may be accelerated with a sophisticated

integrated liquid handling system. We showed that antibody titers from capillary blood serum

are equivalent to titers measured from venous blood (Figure 2). The Infectious Diseases

Society of America Guidelines on the Diagnosis of COVID-19 currently make no

recommendations for or against the use of capillary blood in serological assays due to a

knowledge gap on the subject (*10*). We hope that the success of our study begins to fill this

knowledge gap, paving the way for further proof-of-concept studies using capillary blood. Our

survey revealed that micro blood sampling of capillary blood is a practical, cost-efficient

method using as little as one drop of blood (approximately 30 µL) per sample. Such a small

sample volume would even allow testing of newborns using neonatal heel prick.

Anonymization and web-based reporting

The web-based platform served as an efficient means to conduct this study anonymously

while providing instructions and communicating results to participants. Anonymization was

achieved by randomly barcoded samples without the need to enter personal data. From the

1,154 staff and students at OIST (as of May 2020), 675 samples were received, of which only

41 samples (6.1%) could not be tested due to lack of serum or improper sample collection.

The success of our practical web-based method indicates that this method may be used for

larger epidemiological studies.

Significance of OIST results

The serological survey of students and employees carried out at OIST on Okinawa, Japan, in

August 2020 revealed no seroconversion among this small population. The test has reliably

identified all previously confirmed PCR-positive individuals and controls, with reactivities as

high as 7 times threshold. Our results assert strong confidence in this 2-step assay, which has

received FDA-emergency approval (*2*).

Okinawa has, thus far, enjoyed moderately low numbers of COVID-19 cases among its

population. Other recent serological surveys in Japan, have found seroprevalence as low as

0.43 % (among 44,066 employees and business partners of the company Softbank and

healthcare workers across Japan) (*11*), 0.1 % (1,971 citizens of Tokyo), 0.03 % (3,009 citizens

in Miyagi Prefecture) and 0.17 % (2,970 citizens of Osaka prefecture) (*12*). At such low

seroprevalence, high assay specificity is critical to achieving a high predictive value (*13*, *14*).

Although accurate estimation of the actual seroprevalence among OIST staff and students

(including the 45 % of employees that did not participate in the survey) is not possible,

assuming a seroprevalence between 0.03 % (Tokyo) and 0.43 % (Softbank), with a known

assay specificity of close to 100 % and a sensitivity of 92.5 % for the Mt. Sinai Antibody Test

used here (*9*), we estimate the negative predictivity value of our assay to be greater than

99.9%.

SARS-CoV, SARS-CoV-2 and other human coronaviruses such as NL63 use aceE2 as

receptor (*15*, *16*) mediated by the class-1 fusion protein S before entry through the plasma

membrane, or via a clathrin-dependent endosomal pathway (*17*). MERS-CoV utilizes a similar

mechanism but uses the dipeptidyl peptidase 4 receptor (dpp4) instead (*18*). Dpp4 does not

share sequence and structural similarity to previously identified human coronavirus receptors

such as ACE2 or APN (*15*, *16*, *19*). Convalescent plasma samples from SARS-CoV-infected

patients have moderate cross-reactivity with SARS-CoV-2 spike protein, but no cross-

neutralization (*20*). The assay used here has been shown to have no cross-reactivity with the

seasonal human coronavirus NL63 (*3*). Interestingly, when we tested human convalescent

serum from MERS patients with our ELISA, we found explicit cross-reactivity between MERS

serum and SARS-CoV-2 spike with an antibody titer similar to that of SARS-CoV-2 plasma. Our

sequence alignment indicated only 18.7 % sequence identity between SARS-CoV-2 RBD and

MERS-CoV RBD. On the other hand, we found 32.3 % identity between SARS-CoV-2 and MERS-

CoV spike (S) (Supplementary Figure 3), indicating higher sequence conservation in the other

domains of the spike protein, thus providing a possible explanation for the observed cross-

reactivity. For a given SARS-CoV-2 convalescent serum sample with an anti-spike titer of

>1:1350, the probability of viral neutralization at the FDA-recommended level for

convalescent plasma used for COVID-19 treatment (viral neutralization titer ≥1:160), has been

found to be ≥80 % (*21*). Our data shows strong MERS cross-reactivity with SARS-CoV-2 spike

at titers close to 1:1350. Although most effective neutralizing antibodies against

coronaviruses target the RBD, neutralizing antibodies against SARS-CoV-2 S1-N-terminal

domain (*22*) and SARS-CoV S2 domain (*23*) have also been identified. Our data suggests that

MERS convalescent serum may also contain such neutralizing antibodies against SARS-CoV-2.

Author contributions

M.M., ELISA implementation, validation, analysis. M.M., S.S., N.S., ELISA execution. S.S., test
kit development. T.G.K., N.S., protein expression. T.G.K., protein purification. T.G.K., J.H.K.,
electron microscopy and image analysis. C.B., workflow automation. K.K., sequence
alignment. T.R., S.S.J., website design, sample codes. M.N. provided finger-prick validation
samples and controls. T.M., medical advice and study ethics. M.C., mentoring and advice,
website content, study ethics. M.W. project creation and supervision. M.M., M.W. wrote
initial draft. All authors edited and contributed to the final manuscript.

Data availability

426 Requests for further information or raw data should be directed to the corresponding author.

Acknowledgements

MERS-CoV convalescent sera was kindly provided by Dr Giada Mattiuzzo (NIBSC, United
Kingdom), in collaboration with Dr Manki Song (International Vaccine Institute, South Korea)
Chungnam National University Hospital, and funded by Coalition for Epidemic Preparedness
Innovations (CEPI, Norway). We thank Kieran Deasy and Mouez Lassoued for 3D-printing tube
racks. We are grateful to Mahesh Bandi for advice on statistics and to Alejandro Villar Brillones
for advice on automation. We thank Chris Wu for developing the website's theme and
stylesheets. We thank Pinaki Chakraborty for providing the time and expertise of his
technician C.B. This work was supported by the Platform Project for Supporting Drug
Discovery and Life Science Research (BINDS) from AMED, under grant number
JP18am0101076 (to M.W.). We acknowledge financial support by OPG for a larger serological
study, as well as direct funding from OIST.

References

1.   D. Stadlbauer *et al.*, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a

Serological Assay, Antigen Production, and Test Setup. *Curr. Protoc. Microbiol.* **57**

(2020), doi:10.1002/cpmc.100.

2.   "Accelerated emergency use authorization (EUA) summary COVID-19 ELISA IGG

antibody test (Mount Sinai Laboratory)" (2020), (available at

https://www.fda.gov/media/137029/download).

3.   F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans.

Nat. Med. **26**, 1033–1036 (2020).

4.   S. Q. Zheng *et al.*, MotionCor2: anisotropic correction of beam-induced motion for

improved cryo-electron microscopy. *Nat. Methods*. **14**, 331–332 (2017).

5.   J. Zivanov *et al.*, New tools for automated high-resolution cryo-EM structure

determination in RELION-3. *Elife*. **7** (2018), doi:10.7554/eLife.42166.

6.   S. Pickering *et al.*, Comparative assessment of multiple COVID-19 serological

technologies supports continued evaluation of point-of-care lateral flow assays in

hospital and community healthcare settings. *PLOS Pathog.* **16**, e1008817 (2020).

7.   D. G. Altman, j. M. Bland, Statistics Notes: Diagnostic tests 2: Predictive values. *BMJ*.

309, 102 (1994).

8.   D. Stadlbauer *et al.*, Anti-SARS-CoV -2 Spike Antibodies are Stable in Convalescent

Plasma when Stored at 4° Celsius for at Least 6 Weeks . *Transfusion* (2020),

doi:10.1111/trf.16047.

9.   A. Wajnberg *et al.*, *medRxiv*, in press, doi:10.1101/2020.07.14.20151126.

10. K. E. Hanson *et al.*, Infectious Diseases Society of America Guidelines on the Diagnosis

of COVID-19:Serologic Testing. *Clin. Infect. Dis.* (2020), doi:10.1093/cid/ciaa1343.

11. "Softbank Group Antibody Test Results" (2020), (available at

https://group.softbank/system/files/pdf/antibodytest.pdf).

12. "Tokyo Osaka and Miyagi Prefecture Antibody Possession Survey Results" (2020),

(available at https://www.mhlw.go.jp/content/10906000/000640184.pdf).

13. J. D. Whitman *et al.*, Evaluation of SARS-CoV-2 serology assays reveals a range of test

performance. *Nat. Biotechnol.* **38**, 1174–1183 (2020).

14. N. C. Brownstein, Y. A. Chen, *medRxiv Prepr. Serv. Heal. Sci.*, in press,

doi:10.1101/2020.06.04.20122358.

15. W. Li *et al.*, Angiotensin-converting enzyme 2 is a functional receptor for the SARS

coronavirus. *Nature*. **426**, 450–454 (2003).

16.   F. Li, W. Li, M. Farzan, S. C. Harrison, Structural biology: Structure of SARS coronavirus
478   spike receptor-binding domain complexed with receptor. *Science (80-.).* **309**, 1864–
479   1868 (2005).

480   17.   T. Tang, M. Bidon, J. A. Jaimes, G. R. Whittaker, S. Daniel, Coronavirus membrane
481   fusion mechanism offers a potential target for antiviral development. *Antiviral Res.*
482   **178** (2020), , doi:10.1016/j.antiviral.2020.104792.

483   18.   V. S. Raj *et al.*, Dipeptidyl peptidase 4 is a functional receptor for the emerging human
484   coronavirus-EMC. *Nature*. **495**, 251–254 (2013).

485   19.   N. Wang *et al.*, Structure of MERS-CoV spike receptor-binding domain complexed
486   with human receptor DPP4. *Cell Res.* **23**, 986–993 (2013).

487   20.   H. Lv *et al.*, Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV
488   Infections. *Cell Rep.* **31** (2020), doi:10.1016/j.celrep.2020.107725.

489   21.   E. Salazar *et al.*, Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and
490   receptor binding domain IgG correlate with virus neutralization. *J. Clin. Invest.* (2020),
491   doi:10.1172/jci141206.

492   22.   X. Chi *et al.*, A neutralizing human antibody binds to the N-terminal domain of the
493   Spike protein of SARS-CoV-2. *Science (80-.).* **369**, 650–655 (2020).

494   23.   J. Duan *et al.*, A human SARS-CoV neutralizing antibody against epitope on S2 protein.
495   *Biochem. Biophys. Res. Commun.* **333**, 186–193 (2005).

497
498
Supplemental Figure 1: Antibody Survey Sample Collection Kit and Plate

Design. A. Each blood sampling kit included BD Microtainer® contact-activated

lancet (Becton Dickison, USA), 0.8 ml volume blood collection tube containing

a coagulant and a separator (Greiner bio-one), packaged alcohol wipes,

adhesive bandage, and sticker with an identification barcode and QR code. **B.**

Front page of OIST Antibody Test website. **C.** Plate designs used in the ELISA.

Plates are modified versions of those described previously (*1*).

Supplemental Figure 2: Basic user flow followed by participants to view test results

and answer optional survey

Supplementary Figure 3: Amino acid sequence alignment of spike (S) proteins from SARS-CoV-2 and MERS-CoV. RBD regions (SARS-CoV-2, residue 319-541 and MERS, residue 367-606) are highlighted in red.